Abbott Labs Initiated at Buy by Goldman Sachs
Dow Jones · 2h ago
Abbott Labs Price Target Announced at $121.00/Share by Goldman Sachs
Dow Jones · 2h ago
Goldman Sachs Initiates Coverage On Abbott Laboratories with Buy Rating, Announces Price Target of $121
Benzinga · 2h ago
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
The Motley Fool · 4h ago
Optimistic Buy Rating for Abbott Laboratories on Diverse Portfolio and Growth Prospects
TipRanks · 5h ago
Abbott Stock: Analyst Estimates & Ratings
Abbott Laboratories (ABT) has underperformed the broader market over the past year. The company is renowned for its pioneering diagnostic tools, transformative medical devices, and advanced nutritional offerings. ABT reported its Q1 earnings on May 17. The consensus rating on ABT stock is a "Strong Buy"
Barchart · 5h ago
Implied Volatility Surging for Abbot Laboratories (ABT) Stock Options
NASDAQ · 16h ago
Weekly Report: what happened at ABT last week (0520-0524)?
Weekly Report · 3d ago
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
NASDAQ · 5d ago
Notable ETF Inflow Detected - IWB, MCD, ABT, DHR
NASDAQ · 6d ago
Critical Insights From Abbott Laboratories Analyst Ratings: What You Need To Know
Abbott Laboratories manufactures and markets cardiovascular and diabetes devices. The company's revenue growth rate is lower than its industry peers. Abbott Laboratories has a market capitalization that surpasses industry averages. Abbott has an average 12-month price target of $. The firm has 5 analysts who have evaluated Abbott Laboratories in the last three months.
Benzinga · 05/22 18:00
Abbott Labs Is Maintained at Buy by Citigroup
Dow Jones · 05/22 17:28
Will Medtronic Stock See Higher Levels Post Q4 Results After 5% Gains This Year?
NASDAQ · 05/22 04:03
Investing in Abbott Laboratories (NYSE:ABT) five years ago would have delivered you a 46% gain
Abbott Laboratories has seen its share price drop 12% in the last quarter. The company's return of 34% is below the market return of 100%. The company has grown its earnings per share at 17% a year over the last five years. Over the longer term shareholders have made money, with a gain of 8% per year. We look at the underlying fundamentals of Abbott Laboratories to see if the stock is consistent.
Simply Wall St · 05/21 17:51
Reckitt Benckiser ticks higher amid report activist Eminence Capital takes stake
Activist investor Eminence Capital reported to have taken a small stake in Reckitt Benckiser. Eminence purchased shares in March as Reckitt shares plunged 15% amid a jury verdict against the company over its Enfamil baby formula. The company's shares edged higher in trading on Tuesday.
Seeking Alpha · 05/21 14:32
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
NASDAQ · 05/21 13:29
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose
Jim Cramer recommended buying Dutch Bros Inc. And Canada Goose Holdings Inc. On CNBC's "Mad Money Lightning Round" Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance. Cramer said Nutanix, Inc. Is what the market wants right now.
Benzinga · 05/21 12:44
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
NASDAQ · 05/21 10:59
3 Near-oversold Dividend Aristocrats To Buy Before They Pop
Dividend Aristocrats are companies with consistent dividend growth for at least 25 years. Nucor Corp, Abbott Laboratories and Abbott Laboratories are three near-oversold Dividend aristocrats. The Relative Strength Indicator (RSI) is a popular technical analysis tool to look for oversold stocks. These three companies are on the list of three D dividend Aristocrats to buy.
Barchart · 05/21 02:47
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
NASDAQ · 05/20 18:47
Webull provides a variety of real-time ABT stock news. You can receive the latest news about Abbott Labs through multiple platforms. This information may help you make smarter investment decisions.
About ABT
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.